We’re working to ensure future dementia treatments reach people as quickly as possible.
We work with government bodies, the NHS and medicines regulators to plan ahead, so that future treatments will be made available to those who could benefit from them as soon as possible. We want to make sure the UK is proactive and ambitious about identifying and adopting potential treatments for Alzheimer’s disease and other forms of dementia.
To overcome the potential barriers that could delay the roll-out of new treatments, we need researchers, pharmaceutical companies and the NHS to collaborate early in the research process.
We’ve taken the lead in putting this issue on the agenda and working to find solutions, including:
- Calling for government to establish a Dementia Medicines Taskforce to bring together industry, the NHS, charities and researchers to create more efficient approval processes as well as speed up development of new treatments.
- Engaging with NICE (National Institute for Health and Care Excellence) to help shape the way it evaluates new medicines through membership of the working group examining new procedures.
- Working with other charities by chairing the Charity Medicines Access Coalition to resolve the challenges that can delay or prevent people from being able to access new treatments. This includes high-level meetings with relevant groups and organisations such as the Patient Access to Medicines Partnership to inform and guide policy around access to medicines.
- Developing evidence on the potential impact of future dementia treatments on the NHS, including their cost effectiveness, in our Thinking Differently policy report.
- Outlining the potential challenges the healthcare system faces in preparing for life-changing treatments in our Treatments of Tomorrow report so regulators and the pharmaceutical industry can work together to overcome these challenges.
- Working with the Medicines and Healthcare products Regulatory Agency through the Patient Group Consultative Forum.
- Putting people affected by dementia at the heart of what we do by working directly with them through forums such as our Policy Involvement Panel and Policy Sounding Boards. By talking directly to people affected by dementia we’re able to reflect on their experiences to strengthen our policy work in improving access to treatments for the people who need them.
Our animated video summarises the process that potential new treatments would have to go through before becoming available to people with dementia.
Today a key committee for the European Medicines Agency has recommended refusing an application by the pharmaceutical company Biogen for a licence for the Alzheimer’s drug aducanumab.
Analysis of how future dementia treatments will impact our health system and the taskforce we’re launching to overcome the unique challenges these treatments present.
Our report outlines a number of challenges and pressures in the healthcare system that may present problems for the roll-out of potential disease-modifying treatments of the future.